AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25559048 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal vulvovaginal symptoms
Number of subjects: 34
Study 25559048 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum or CVL cytokines
Number of subjects: 34
Study 25559400 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fasting plasma glucose (FPG) levels during weight gain
Number of subjects: 144
Study 25559400 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 144
Study 25559400 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline fasting plasma glucose (FPG)
Number of subjects: 144
Study 25559400 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 144
Study 25559651 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D speckle-tracking echocardiography and cardiac magnetic resonance imaging (CMR)
Number of subjects: 95
Study 25560174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine-ER 5 mg
Number of subjects: 429
Study 25560174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine-ER 10 mg
Number of subjects: 429
Study 25560174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 25560203 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia using 0.375% or 0.5% ropivacaine 15 mL, followed by continuous infusion of 0.15% ropivacaine 2 mL·hr(-1) with fentanyl 8 μg·hr(-1) postoperatively
Number of subjects: 439
Study 25560712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy stopped after negative D-dimer test results
Number of subjects: 410
Study 25560712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy stopped after negative D-dimer test results in men
Number of subjects: 410
Study 25560712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy stopped after negative D-dimer test results in women not associated with estrogen therapy
Number of subjects: 410
Study 25560712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy stopped after negative D-dimer test results in women associated with estrogen therapy
Number of subjects: 410
Study 25560819 — intervention group
Group type: EXPERIMENTAL
Intervention: External facilitation (EF) - a one-year multifaceted intervention including support, guidance, practice audits, and feedback.
Number of subjects: 101
Study 25560819 — intervention group
Group type: COMPARATOR
Intervention: Educational outreach visits (EOVs) - one session of three hours of lectures about the guidelines.
Number of subjects: 101
Study 25562355 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 2038
Study 25563429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lestaurtinib 140 mg twice daily (maximum tolerated dose)
Number of subjects: 34
Study 25563429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lestaurtinib (doses lower than 140 mg)
Number of subjects: 34
Study 25563429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lestaurtinib
Number of subjects: 34
Study 25563640 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraplaque hemorrhage (IPH)
Number of subjects: 101
Study 25563640 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin/ruptured fibrous cap (TRFC)
Number of subjects: 101
Study 25563640 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI detection of infarcts
Number of subjects: 101
Study 25564232 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy individuals
Number of subjects: 17
Study 25564232 — intervention group
Group type: COMPARATOR
Intervention: Temporal lobe epilepsy (TLE) patients
Number of subjects: 17
Study 25564282 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic warnings applied to the front and back of smokers' cigarette packs
Number of subjects: 76
Study 25564781 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lumen endotracheal tube (SLT)
Number of subjects: 44
Study 25564781 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen endotracheal tube (DLT)
Number of subjects: 44
Study 25564820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin conjugates (Bc)
Number of subjects: 0
Study 25564820 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of cholestasis
Number of subjects: 0
Study 25564820 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum albumin levels
Number of subjects: 0
Study 25564897 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant paclitaxel and trastuzumab
Number of subjects: 406
Study 25565363 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of at least one additional chronic comorbidity
Number of subjects: 228
Study 25565363 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 228
Study 25565363 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of pack years
Number of subjects: 228
Study 25565363 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1
Number of subjects: 228
Study 25565363 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of at least one additional comorbidity
Number of subjects: 228
Study 25565457 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compression rates between 100 and 120 compressions/min
Number of subjects: 10371
Study 25565457 — intervention group
Group type: COMPARATOR
Intervention: Compression rates <80, 80-99, 120-139, ≥140 compressions/min
Number of subjects: 10371
Study 25565457 — intervention group
Group type: COMPARATOR
Intervention: Reference group (100-119 compressions/min)
Number of subjects: 10371
Study 25565635 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblast preparations with genomic abnormalities
Number of subjects: 10
Study 25565635 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged cultures of myoblasts
Number of subjects: 10
Study 25565635 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoblasts in soft agar or in vivo
Number of subjects: 10
Study 25565635 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular analysis of individual p53 transcripts
Number of subjects: 10
Study 25565635 — intervention group
Group type: EXPERIMENTAL
Intervention: CGH array and exome sequencing
Number of subjects: 10
Study 25565885 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 300 mg/d
Number of subjects: 1233
Study 25566367 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific group cognitive behavioral therapy (CS-CBT)
Number of subjects: 247
Study 25566367 — intervention group
Group type: COMPARATOR
Intervention: Standard group cognitive behavioral therapy (control)
Number of subjects: 247
Study 25566367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups receive transdermal nicotine patch (TNP) for 8 weeks
Number of subjects: 247
Study 25566369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 25566369 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0
Study 25566369 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study 25566369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 0
Study 25566379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogue-based psychosocial nursing intervention in primary care (individual or group encounters)
Number of subjects: 25
Study 25566379 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews focusing on participant experiences
Number of subjects: 25
Study 25566383 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored smoking cessation program
Number of subjects: 400
Study 25566383 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation program (Courage to Quit)
Number of subjects: 400
Study 25566387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR) + D-cycloserine (DCS)
Number of subjects: 40
Study 25566387 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Remediation (CR) + placebo
Number of subjects: 40
Study 25566391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (16 sessions)
Number of subjects: 0
Study 25566391 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dynamic psychotherapy (16 sessions)
Number of subjects: 0
Study 25566392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure Procrastination Scale
Number of subjects: 710
Study 25566392 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrational Procrastination Scale
Number of subjects: 710
Study 25566392 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility to Temptation Scale
Number of subjects: 710
Study 25566998 — intervention group
Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia (SARA)
Number of subjects: 592
Study 25566998 — intervention group
Group type: EXPERIMENTAL
Intervention: Inventory of Non-Ataxia Signs (INAS)
Number of subjects: 592
Study 25566998 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinocerebellar Ataxia Functional Index (SCAFI)
Number of subjects: 592
Study 25566998 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive phonemic verbal fluency test
Number of subjects: 592
Study 25566998 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADL) part of the Friedreich's Ataxia Rating Scale
Number of subjects: 592
Study 25566998 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D (health-related quality of life)
Number of subjects: 592
Study 25567235 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally relevant functioning assessment instrument (FAI)
Number of subjects: 142
Study 25567235 — intervention group
Group type: COMPARATOR
Intervention: World Health Organization's Disability Assessment Schedule (WHODAS) 12-item version
Number of subjects: 142
Study 25567425 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications (olanzapine, perphenazine, quetiapine, risperidone, or ziprasidone)
Number of subjects: 520
Study 25567425 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic treatment (after 6 months)
Number of subjects: 520
Study 25567501 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA pregnancies (isolated MMA)
Number of subjects: 17
Study 25568299 — intervention group
Group type: EXPERIMENTAL
Intervention: Dystroglycanopathy cohort
Number of subjects: 30
Study 25568347 — intervention group
Group type: EXPERIMENTAL
Intervention: R-MPV chemotherapy (rituximab, methotrexate 3.5 g/m(2), procarbazine, vincristine)
Number of subjects: 32
Study 25568347 — intervention group
Group type: EXPERIMENTAL
Intervention: HDC with thiotepa, cyclophosphamide, and busulfan followed by ASCT
Number of subjects: 32
Study 25568347 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 32
Study 25572023 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Element stent
Number of subjects: 1014
Study 25572091 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT with 70%-90% SUVmax thresholds
Number of subjects: 39
Study 25572091 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT with 30%-60% SUVmax thresholds
Number of subjects: 39
Study 25572091 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT during radiotherapy
Number of subjects: 39
Study 25572193 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine AQP1 concentrations in RCC patients (n=47)
Number of subjects: 105
Study 25572193 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine PLIN2 concentrations in RCC patients (n=47)
Number of subjects: 105
Study 25572193 — intervention group
Group type: COMPARATOR
Intervention: Urine AQP1 concentrations in bladder cancer patients (n=22)
Number of subjects: 105
Study 25572193 — intervention group
Group type: COMPARATOR
Intervention: Urine PLIN2 concentrations in bladder cancer patients (n=22)
Number of subjects: 105
Study 25572193 — intervention group
Group type: COMPARATOR
Intervention: Urine AQP1 concentrations in prostate cancer patients (n=27)
Number of subjects: 105
Study 25572193 — intervention group
Group type: COMPARATOR
Intervention: Urine PLIN2 concentrations in prostate cancer patients (n=27)
Number of subjects: 105
Study 25572193 — intervention group
Group type: COMPARATOR
Intervention: Urine AQP1 concentrations in chromophobe tumors (n=7)
Number of subjects: 105
Study 25572193 — intervention group
Group type: COMPARATOR
Intervention: Urine PLIN2 concentrations in chromophobe tumors (n=7)
Number of subjects: 105
Study 25572193 — intervention group
Group type: COMPARATOR
Intervention: Urine AQP1 concentrations in benign renal oncocytomas (n=9)
Number of subjects: 105
Study 25572193 — intervention group
Group type: COMPARATOR
Intervention: Urine PLIN2 concentrations in benign renal oncocytomas (n=9)
Number of subjects: 105
Study 25572193 — intervention group
Group type: COMPARATOR
Intervention: Urine AQP1 concentrations in angiomyolipomas (n=7)
Number of subjects: 105
Study 25572193 — intervention group
Group type: COMPARATOR
Intervention: Urine PLIN2 concentrations in angiomyolipomas (n=7)
Number of subjects: 105
Study 25572329 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat 30 mg 3 times per week, every other week, in combination with bevacizumab 10 mg/kg every other week
Number of subjects: 39
Study 25572505 — intervention group
Group type: EXPERIMENTAL
Intervention: Major HAIs (pneumonia, sepsis, Clostridium difficile colitis)
Number of subjects: 4320
Study 25572505 — intervention group
Group type: EXPERIMENTAL
Intervention: Major HAIs
Number of subjects: 4320
Study 25572505 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmissions due to major HAIs
Number of subjects: 4320
Study 25572507 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 5800
Study 25572917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.6 mg/m² intravenously once-weekly for six cycles with dexamethasone 40 mg on the day of and day after bortezomib
Number of subjects: 50
Study 25573455 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term electrocardiography (ECG) Holter monitoring
Number of subjects: 98
Study 25573884 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased glycemic variability (assessed by MAGE) in women
Number of subjects: 87
Study 25573884 — intervention group
Group type: COMPARATOR
Intervention: Cardiac autonomic modulation measures in men
Number of subjects: 87
Study 25573987 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 49
Study 25573987 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with rituximab
Number of subjects: 49
Study 25574042 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel daily disposable lenses (SiHyDD)
Number of subjects: 1171
Study 25574042 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel daily disposable lenses (HydDD)
Number of subjects: 1171
Study 25574088 — intervention group
Group type: EXPERIMENTAL
Intervention: TNBS treatment in rats
Number of subjects: 12
Study 25574088 — intervention group
Group type: COMPARATOR
Intervention: IBS patients
Number of subjects: 12
Study 25574704 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal estimated insulin resistance in the first half of pregnancy
Number of subjects: 804
Study 25574704 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal glucose levels in the second half of pregnancy
Number of subjects: 804
Study 25574704 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein in the first half of pregnancy
Number of subjects: 804
Study 25574704 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fatty acid levels in the second half of pregnancy
Number of subjects: 804
Study 25575503 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence during physician consultations
Number of subjects: 0
Study 25575503 — intervention group
Group type: COMPARATOR
Intervention: No parental presence during physician consultations
Number of subjects: 0
Study 25575538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus low-dose dexamethasone (Pom-Dex)
Number of subjects: 50
Study 25576273 — intervention group
Group type: EXPERIMENTAL
Intervention: OMEGA stent (bare platinum chromium element stent)
Number of subjects: 328
Study 25576353 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy
Number of subjects: 1967
Study 25576647 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural impulse control measured in the dorsolateral prefrontal cortex (DLPFC) using fMRI at T0 (beginning of follow-up) and T12 (end of follow-up).
Number of subjects: 0
Study 25576647 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral measures of control during the follow-up period.
Number of subjects: 0
Study 25576647 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural signals from DLPFC.
Number of subjects: 0
Study 25577718 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib, sorafenib, axitinib, temsirolimus, or temsirolimus and interferon-α
Number of subjects: 2749
Study 25578404 — intervention group
Group type: EXPERIMENTAL
Intervention: WELCH score with a cut-off point of 25
Number of subjects: 525
Study 25578404 — intervention group
Group type: EXPERIMENTAL
Intervention: WELCH score
Number of subjects: 525
Study 25579459 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anthracycline regimens followed by nanoparticle albumin-bound paclitaxel (nab-PTX) 260 mg/m² plus trastuzumab, administered every 3 weeks for 4 cycles.
Number of subjects: 44
Study 25579459 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anthracycline regimens followed by nanoparticle albumin-bound paclitaxel (nab-PTX) plus trastuzumab.
Number of subjects: 44
Study 25579693 — intervention group
Group type: EXPERIMENTAL
Intervention: OsteoACTIVE rehabilitation program (weight vests and patient education)
Number of subjects: 42
Study 25579865 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin challenge (1 ng/kg LPS)
Number of subjects: 148
Study 25581108 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1192
Study 25581108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 1192
Study 25581108 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1192
Study 25581108 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1192
Study 25581108 — intervention group
Group type: COMPARATOR
Intervention: Nonvitamin K antagonist oral anticoagulants
Number of subjects: 1192
Study 25581108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvitamin K antagonist oral anticoagulants started early (median 4 days after stroke onset)
Number of subjects: 1192
Study 25581596 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative SIB-IMRT
Number of subjects: 201
Study 25581596 — intervention group
Group type: COMPARATOR
Intervention: Non-RT (no postoperative RT)
Number of subjects: 201
Study 25583164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 12 or 24 weeks
Number of subjects: 497
Study 25583164 — intervention group
Group type: COMPARATOR
Intervention: HCV-monoinfected patients
Number of subjects: 497
Study 25583442 — intervention group
Group type: COMPARATOR
Intervention: Control group (glucose-tolerant)
Number of subjects: 54
Study 25583442 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes group
Number of subjects: 54
Study 25584134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate 0.05% gel applied for two consecutive days to treatment areas up to 100cm(2)
Number of subjects: 81
Study 25584193 — intervention group
Group type: EXPERIMENTAL
Intervention: Core strength training on unstable surfaces (CSTU)
Number of subjects: 27
Study 25584193 — intervention group
Group type: COMPARATOR
Intervention: Core strength training on stable surfaces (CSTS)
Number of subjects: 27
Study 25584193 — intervention group
Group type: EXPERIMENTAL
Intervention: Core strength training (CSTU and CSTS combined)
Number of subjects: 27
Study 25585031 — intervention group
Group type: EXPERIMENTAL
Intervention: 2013 AHA/ACC guidelines approach (maximization of statin therapy at high-intensity for patients aged ≤75 years and moderate- or high-intensity for patients >75 years)
Number of subjects: 1602
Study 25585031 — intervention group
Group type: COMPARATOR
Intervention: Previous guidelines approach (achievement of LDL-C target < 1.8 mmol/l, reduction of LDL-C ≥ 50% or intensification of statin)
Number of subjects: 1602
Study 25585528 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg and darunavir/ritonavir 800/100 mg once-daily regimen
Number of subjects: 54
Study 25585572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 144
Study 25586396 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin administered orally in one or two supervised sessions in addition to Motivational Enhancement Therapy
Number of subjects: 10
Study 25586396 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin session intensity
Number of subjects: 10
Study 25586626 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (n=76)
Number of subjects: 139
Study 25586626 — intervention group
Group type: COMPARATOR
Intervention: intensive lifestyle intervention (n=63)
Number of subjects: 139
Study 25586686 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 magnetic resonance (T2MR)
Number of subjects: 1801
Study 25586726 — intervention group
Group type: EXPERIMENTAL
Intervention: ϵ-aminocaproic acid (EACA)
Number of subjects: 20
Study 25586726 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing recommendations for EACA based on weight: weight <25 kg, 100 mg kg(-1) loading dose and 40 mg kg(-1) h(-1) infusion; weight ≤25 kg-<50 kg, 100 mg kg(-1) loading dose and 35 mg kg(-1) h(-1) infusion; weight ≥50 kg, 100 mg kg(-1) loading dose and 30 mg kg(-1) h(-1) infusion.
Number of subjects: 20
Study 25586728 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical checklist use
Number of subjects: 45591
Study 25586952 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating radiation dose with simultaneous integrated boost (SIB) to the pre-treatment 50% SUVmax area of the primary tumor, up to 70Gy
Number of subjects: 25
Study 25587040 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) in first complete remission
Number of subjects: 522
Study 25587040 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) in patients with postinduction minimal residual disease (MRD) ≥10(-3)
Number of subjects: 522
Study 25587040 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (SCT) in B-cell precursor ALL patients with focal IKZF1 gene deletion
Number of subjects: 522